Drug Trial News

RSS

New COVID-19 vaccine proven to be safe and effective in late-stage clinical testing

A COVID-19 vaccine developed at the University of Washington School of Medicine has proven safe and effective in late-stage clinical testing.

25 Apr 2022

New data may change the standard of care for patients with advanced non-small cell lung cancer

The phase 2 clinical trial of a multi-center study known as the COAST clinical trial has demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center and participating organizations.

25 Apr 2022

Monoclonal-antibody combination AZD7442 prevents COVID-19

In a recent study published in The New England Journal of Medicine, the researchers examined the monoclonal-antibody combination AZD7442 to prevent coronavirus disease 2019 (COVID-19).

25 Apr 2022

New drug shows promise in treating a movement disorder associated with Huntington's disease

A new drug has proven beneficial in treating a movement disorder commonly associated with Huntington's disease, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.

13 Apr 2022

Aprotinin could inhibit virus replications by preventing SARS-CoV-2 entry into host cells

A clinical study from Spain recently confirmed laboratory experiments made by researchers of Goethe University Frankfurt and University of Kent who showed that the protease inhibitor aprotinin prevented cells to be infected by SARS-CoV2.

12 Apr 2022

Thousands more vulnerable patients are eligible to receive the UK’s second antiviral for COVID-19

Thousands more vulnerable people in England are now eligible to receive the UK's second oral antiviral treatment for Covid.

12 Apr 2022

Drug used to treat lung cancer could help improve survival rates for bladder cancer patients

Scientists from the University of Sheffield have discovered a drug already used to treat lung cancer could help to improve survival rates for bladder cancer patients.

11 Apr 2022

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

vaccines against the virus, but unfortunately, HIV has numerous defense mechanisms that prevent a person's immune system from mounting an effective response following HIV vaccination.

11 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Nanocell COVID-19 vaccine elicits potent neutralizing response

A new study describes the high level of neutralizing antibodies elicited by a nanocell vaccine against SARS-CoV-2 in vitro, in vivo, and human studies.

11 Apr 2022

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived from donated umbilical cord blood, combined with a novel bispecific antibody known as AFM13 that targets CD16A and CD30, achieved effective responses in patients with pretreated and refractory CD30+ lymphoma.

11 Apr 2022

Study: Less than half of clinical trials report race/ethnicity data

Clinical trials represent one the largest investments of collective resources in science. These studies, which recruit participants and rigorously evaluate new interventions and therapeutics, aim to advance scientific knowledge and improve patient treatment.

11 Apr 2022

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A bispecific antibody elicited an 89 percent overall response rate in patients with relapsed or refractory CD30+ lymphoma, according to results from a phase I/II clinical trial presented at the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Preliminary data from clinical trial reveals safety, efficacy of new CAR T-cell therapy for solid tumors

A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data from a phase I/II clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

10 Apr 2022

Novel therapy advances to clinical trial for the treatment of glioblastoma

A novel therapy studied at the Medical College of Wisconsin (MCW) Cancer Center has led to a clinical trial for the treatment of glioblastoma, a rare and aggressive form of brain cancer, yet the most common primary brain tumor in adults.

10 Apr 2022

Combination immunotherapy reverses resistance to PD-1 inhibitors in patients with advanced melanoma

Patients with advanced melanoma whose cancer does not respond to treatment with widely used immunotherapy drugs known as PD-1 inhibitors are often switched to treatment with a second type of immunotherapy drug – a CTLA-4 inhibitor such as the drug ipilimumab.

8 Apr 2022

City of Hope's late-breaking clinical trial data to be presented at AACR

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, will present late-breaking and clinical trial findings at this year's American Association for Cancer Research Annual Meeting, which begins today.

8 Apr 2022

Many clinical trials fail to account for previous or ongoing studies, researchers show

Clinical trials are a pivotal tool for assessing the safety and efficacy of medical interventions, but sponsors often provide incomplete information for assessing their ethical justification.

8 Apr 2022

HIV drug stops disease progression in 25% of patients with fourth-line metastatic colorectal cancer

New clinical research shows that lamivudine, a reverse transcriptase inhibitor widely used in HIV therapy, stopped disease progression in 25% of patients with fourth-line metastatic colorectal cancer.

5 Apr 2022

Previous
1
...
47
48
49
50
51
52
53
...
1156
Next

Drug Trial News

New COVID-19 vaccine proven to be safe and effective in late-stage clinical testing

New data may change the standard of care for patients with advanced non-small cell lung cancer

Monoclonal-antibody combination AZD7442 prevents COVID-19

New drug shows promise in treating a movement disorder associated with Huntington's disease

Aprotinin could inhibit virus replications by preventing SARS-CoV-2 entry into host cells

Thousands more vulnerable patients are eligible to receive the UK’s second antiviral for COVID-19

Drug used to treat lung cancer could help improve survival rates for bladder cancer patients

Alternative anti-HIV strategy generates promising results in a phase I clinical trial

New study reveals oral opaganib's potent in vitro activity against Omicron

Nanocell COVID-19 vaccine elicits potent neutralizing response

NK cells combined with bispecific antibody achieve effective responses in patients with lymphoma

Study: Less than half of clinical trials report race/ethnicity data

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

NSCLC patients treated with KRAS G12C inhibitor sotorasib may receive long-term clinical benefit

Preliminary data from clinical trial reveals safety, efficacy of new CAR T-cell therapy for solid tumors

Novel therapy advances to clinical trial for the treatment of glioblastoma

Combination immunotherapy reverses resistance to PD-1 inhibitors in patients with advanced melanoma

City of Hope's late-breaking clinical trial data to be presented at AACR

Many clinical trials fail to account for previous or ongoing studies, researchers show

HIV drug stops disease progression in 25% of patients with fourth-line metastatic colorectal cancer

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News